{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:32:19Z","timestamp":1790839939166,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.ijantimicag.2008.07.031","type":"journal-article","created":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T03:26:22Z","timestamp":1226287582000},"page":"130-136","source":"Crossref","is-referenced-by-count":30,"title":["Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)"],"prefix":"10.1016","volume":"33","author":[{"given":"Sam K.","family":"Bouchillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Iredell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Barkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Dowzicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2008.07.031_bib1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/sur.2006.7.537","article-title":"In vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002\u20132004: results from SMART (Study for Monitoring Antimicrobial Resistance Trends)","volume":"7","author":"Bochicchio","year":"2006","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/mdr.2000.6.213","article-title":"Genetic relatedness of multidrug-resistant, methicillin (oxacillin)-resistant Staphylococcus aureus bloodstream isolates from SENTRY antimicrobial resistance surveillance centers worldwide, 1998","volume":"6","author":"Diekema","year":"2000","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jac\/dkl199","article-title":"In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)","volume":"58","author":"Rossi","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2008.07.031_bib5","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/499406","article-title":"The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs","volume":"42","author":"Cosgrove","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.clinthera.2006.08.011","article-title":"Tigecycline: a glycylcycline antimicrobial agent","volume":"28","author":"Doan","year":"2006","journal-title":"Clin Ther"},{"issue":"Suppl. 5","key":"10.1016\/j.ijantimicag.2008.07.031_bib7","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 5","key":"10.1016\/j.ijantimicag.2008.07.031_bib8","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin\u2013aztreonam","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib9","unstructured":"National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed. Approved standard M7-A6. Wayne, PA: NCCLS; 2003."},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib10","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. M100-S16. Wayne, PA: CLSI; 2006."},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib11","unstructured":"Wyeth Pharmaceuticals Inc. Tygacil\u00ae product insert. Philadelphia, PA: Wyeth; 2005. http:\/\/www.wyeth.com\/hcp\/tygacil [accessed 31 March 2008]."},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3201\/eid1301.060716","article-title":"Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization","volume":"13","author":"Sunenshine","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1469-0691.2005.01351.x","article-title":"Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001\u20132004)","volume":"12","author":"Gales","year":"2006","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 5","key":"10.1016\/j.ijantimicag.2008.07.031_bib14","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1086\/431673","article-title":"In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections","volume":"41","author":"Bradford","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diagmicrobio.2005.05.002","article-title":"Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit","volume":"52","author":"Sader","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0924-8579(02)00050-X","article-title":"Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific region: report from the SENTRY antimicrobial surveillance program, 1998\u20131999","volume":"20","author":"Turnidge","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib17","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1086\/432940","article-title":"Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy","volume":"41","author":"Lautenbach","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib18","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/archinte.165.12.1375","article-title":"Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: variability by site of infection","volume":"165","author":"Hyle","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib19","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3346\/jkms.2005.20.6.961","article-title":"Emergence and wide dissemination of CTX-M-type ESBLs, and CMY-2- and DHA-1-type AmpC \u03b2-lactamases in Korean respiratory isolates of Klebsiella pneumoniae","volume":"20","author":"Yum","year":"2005","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijantimicag.2006.04.010","article-title":"In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)","volume":"28","author":"Hsueh","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0732-8893(01)00353-4","article-title":"Prevalence of extended spectrum (-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY antimicrobial surveillance program (1998\u201399)","volume":"42","author":"Bell","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib22","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/jac\/dki117","article-title":"In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 study for monitoring antimicrobial resistance trends (SMART)","volume":"55","author":"Paterson","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.diagmicrobio.2006.02.001","article-title":"Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries","volume":"55","author":"Ko","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib24","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3349\/ymj.2004.45.4.598","article-title":"Increasing prevalence of vancomycin-resistant enterococci, and cefoxitin-, imipenem- and fluoroquinolone-resistant Gram-negative bacilli: a KONSAR study in 2002","volume":"45","author":"Lee","year":"2004","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.diagmicrobio.2005.06.010","article-title":"Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib26","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1128\/AAC.48.6.2049-2055.2004","article-title":"Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001","volume":"48","author":"Christiansen","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/jac\/dki437","article-title":"Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations","volume":"57","author":"Jones","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jac\/dkg074","article-title":"Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific","volume":"51","author":"Bell","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0732-8893(03)00012-9","article-title":"Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY antimicrobial surveillance program (1997\u20132000)","volume":"46","author":"Mutnick","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3349\/ymj.2006.47.1.43","article-title":"Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KONSAR surveillance","volume":"47","author":"Lee","year":"2006","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diagmicrobio.2004.12.013","article-title":"Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program","volume":"52","author":"Ross","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib32","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/jac\/dkm002","article-title":"Tigecycline resistance in Australian antibiotic-resistant Gram-negative bacteria","volume":"59","author":"Iredell","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/jac\/dkl441","article-title":"Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report","volume":"59","author":"Peleg","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib34","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.00373-06","article-title":"Effect of tigecycline on normal oropharyngeal and intestinal microflora","volume":"50","author":"Nord","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.07.031_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1128\/JCM.01588-06","article-title":"Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp.","volume":"45","author":"Jones","year":"2007","journal-title":"J Clin Microbiol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857908003816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857908003816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T09:52:58Z","timestamp":1545645178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857908003816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0924857908003816"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2008.07.031","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}